rHuEPO lncreases Urinary Excretion of Fibrin Degradation Products in Haemodialysed Patients

Thromb Haemost 1993; 70(02): 373-374
DOI: 10.1055/s-0038-1649586

Letter to the Editor

Schattauer GmbH Stuttgart

Authors

Raynald Gareau

¹Dept. Chimie-Biologie, Université du Québec à Trois-Rivières, Québec, Canada, G9A 5H7
Marie-Guylaine Gagnon

¹Dept. Chimie-Biologie, Université du Québec à Trois-Rivières, Québec, Canada, G9A 5H7
Christiane Ayotte

²National Institute for Scientific Research (INRS-Santé) , 245 Hymus, Pointe-Claire, Québec, Canada H9R 1G6
Claire Chénard

¹Dept. Chimie-Biologie, Université du Québec à Trois-Rivières, Québec, Canada, G9A 5H7
Guy R Brisson

²National Institute for Scientific Research (INRS-Santé) , 245 Hymus, Pointe-Claire, Québec, Canada H9R 1G6

References
1 Eschbach R, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end stage renal disease with recombinant human erythropoietin. New Engl J Med 1987; 316: 73-77
2 Hirasawa Y. Exercise function and rHuEPO. Jap J Clin Dial 1989; 5: 929-935
3 Gareau R, Brisson GR, Ayotte C, Dubé J, Caron C. Erythropoietin doping in athletes: possible detection through measurement of von Willebrand factor and D-dimer activity?. Thromb Haemostas 1992; 68: 487-488
4 Moia M, Mannuci PM, Vizzoto L, Casati S, Cattaneo M, Ponticelli C. Improvement in haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; ii: 1227-1229
5 Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C. Benefits and risks of protracted treatment with human recombinant ery-thropoietin in patients having haemodialysis. Br Med J 1987; 295: 1017-1020
6 Sakakibara K, Nagase M, Takada Y, Kakada A. Relationship between urinary fibrinogen degradation products and various types of chronic nephritis. Thromb Res 1987; 45: 403-411
7 Szewczuk J, Mazerska M, Malyszko J, Kalinowski M, Mysliwiec M. Increase in fibrinolytic activity after erythropoietin therapy. Thromb Haemostas 1992; 67: 284